FDA approves new drug to prevent sickle cell pain, organ damage

National News

This undated image provided by Novartis shows bottles of Novartis’s Adakveo. U.S. regulators have approved the new sickle cell disease medicine that can prevent extremely painful, dangerous “crises” in which misshapen blood cells clump together, reducing blood and oxygen flow. (Novartis via AP)

(AP) — U.S. regulators on Friday approved a new medicine that can prevent some extremely painful sickle cell disease flare-ups.

The Food and Drug Administration approved Novartis AG’s Adakveo for patients 16 and older. The monthly infusion, which halves occurrences of sickle cell pain episodes, will carry a list price of roughly $85,000 to $113,000 per year, depending on dosing. Insured patients generally will pay less.

Sickle cell disease is one of the most common inherited blood disorders, affecting about 100,000 Americans, most of them black, and about 300 million people worldwide.

Its hallmark is periodic episodes in which red blood cells stick together, blocking blood from reaching organs and small blood vessels. That causes intense pain and cumulative organ damage that shortens the lives of people with the disease.

“The duration and severity of these pain crises worsens with aging. Often patients die during one of these crises,” said Dr. Biree Andemariam, chief medical officer of the Sickle Cell Disease Association of America.

Andemariam, a former Novartis adviser, said the drug appears to work better the longer patients receive it.

The Swiss drugmaker is continuing patient testing to determine whether Adakveo, also known as crizanlizumab, lengthens patients’ lives, said Ameet Mallik, the company’s head of oncology and blood disorder research.

He said severe pain episodes send U.S. patients to emergency departments about 200,000 times per year. About 85% are hospitalized for days to a week, running up big bills.

The debilitating condition also causes anemia, delayed growth, vision damage and painful swelling in hands and feet, making it hard for some people to maintain jobs or attend school.

Current treatments include a 21-year-old cancer drug called hydroxyurea and Endari, approved in 2017.

In patient studies, Endari reduced the frequency of pain episodes about 25% and hydroxyurea reduced them by half. Hydroxyurea can have serious side effects and requires weekly blood tests. Both drugs have complicated dosing and don’t work — or stop working — in some patients.

In a one-year study of 198 patients, those getting the higher of two Adakveo doses averaged 1.6 pain episodes over that year and 36% had none. A comparison group on placebo averaged three pain episodes that year and 17 percent had none. Adakveo’s side effects included influenza and high fever.

Danielle Jamison, of Islandton, South Carolina, has suffered with sickle cell pain episodes since shortly after birth. The 35-year-old previously had a half-dozen pain crises requiring hospital trips each year. Those lessened by about half when she began taking hydroxyurea nine years ago.

She hasn’t been in the hospital since she started taking crizanlizumab two years ago as part of a patient study. She still has mild daily pain, but she said she can now take care of her home and drive her 9-year-old daughter to activities.

“It’s made a huge difference in how much I’m able to do,” Jamison said.

All three drugs work through different mechanisms, so doctors may switch patients to Adakveo or to add it to their current treatment, said Andemariam, head of the University of Connecticut’s sickle cell treatment and research program.

Meanwhile, numerous drugs to treat sickle cell disease and gene therapies to possibly cure it are being tested.

Copyright 2019 Nexstar Broadcasting, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Recent Videos

Amber's Monday Morning One Minute Forecast 12/9

Thumbnail for the video titled "Amber's Monday Morning One Minute Forecast 12/9"

Arctic Air Highlights The Week

Thumbnail for the video titled "Arctic Air Highlights The Week"

Meals on Wheels

Thumbnail for the video titled "Meals on Wheels"

Top Plays

Thumbnail for the video titled "Top Plays"

Sunday Snow

Thumbnail for the video titled "Sunday Snow"

Military Housing Concerns

Thumbnail for the video titled "Military Housing Concerns"

Student Delegates

Thumbnail for the video titled "Student Delegates"

Refugee Meeting Update

Thumbnail for the video titled "Refugee Meeting Update"

Robert's one Minute Forecast 12-8

Thumbnail for the video titled "Robert's one Minute Forecast 12-8"

Holiday Travel Scams

Thumbnail for the video titled "Holiday Travel Scams"

HS Wrestling

Thumbnail for the video titled "HS Wrestling"

Girl's Basketball

Thumbnail for the video titled "Girl's Basketball"

Boy's Basketball

Thumbnail for the video titled "Boy's Basketball"

Ascension Google

Thumbnail for the video titled "Ascension Google"

Touchmark Tempos

Thumbnail for the video titled "Touchmark Tempos"

Protecting Privacy/Data

Thumbnail for the video titled "Protecting Privacy/Data"

Robert's One Minute Forecast 12-7-19

Thumbnail for the video titled "Robert's One Minute Forecast 12-7-19"

Lego League

Thumbnail for the video titled "Lego League"

Parkinson's Disease

Thumbnail for the video titled "Parkinson's Disease"

U-Mary vs Minot State hockey

Thumbnail for the video titled "U-Mary vs Minot State hockey"
More Video

KX News Trending Stories

Don't Miss

Daily Pledge

More Daily Pledge